Hwail Pharmaceutical Co.Ltd (061250) — Cash Flow Quality Index
Hwail Pharmaceutical Co.Ltd (061250) has a Cash Flow Quality Index of 17.57x as of September 2025. Operating cash flow of ₩6.82 Billion exceeds net income of ₩388.45 Million, indicating high earnings quality where cash backs reported profits. Explore 061250 cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Hwail Pharmaceutical Co.Ltd Cash Flow Quality Index (2011–2024)
Historical Cash Flow Quality Index for Hwail Pharmaceutical Co.Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Hwail Pharmaceutical Co.Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year earnings quality comparison for Hwail Pharmaceutical Co.Ltd. For live market cap and the full company financial profile, see Hwail Pharmaceutical Co.Ltd stock valuation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.80x | ₩11.63 Billion | ₩6.48 Billion | ▼ -1.3% |
| 2023 | 1.82x | ₩7.02 Billion | ₩3.86 Billion | ▼ -74.3% |
| 2021 | 7.07x | ₩20.09 Billion | ₩2.84 Billion | ▲ +9934.7% |
| 2020 | -0.07x | ₩-201.69 Million | ₩2.81 Billion | ▼ -106.2% |
| 2019 | 1.16x | ₩3.69 Billion | ₩3.19 Billion | ▼ -18.1% |
| 2018 | 1.41x | ₩7.17 Billion | ₩5.08 Billion | ▼ -54.9% |
| 2017 | 3.13x | ₩8.34 Billion | ₩2.67 Billion | ▲ +108.3% |
| 2016 | 1.50x | ₩9.58 Billion | ₩6.38 Billion | ▲ +218.6% |
| 2015 | -1.27x | ₩-6.90 Billion | ₩5.45 Billion | ▼ -87.9% |
| 2014 | -0.67x | ₩-2.78 Billion | ₩4.13 Billion | ▼ -140.7% |
| 2013 | 1.66x | ₩6.97 Billion | ₩4.21 Billion | ▲ +734.1% |
| 2012 | 0.20x | ₩1.00 Billion | ₩5.06 Billion | ▼ -88.2% |
| 2011 | 1.68x | ₩7.86 Billion | ₩4.69 Billion | — |